Five things for pharma marketers to know: Thursday, January 28, 2016


1. Vertex Pharmaceuticals reported that its new cystic-fibrosis drug Orkambi brought in $219.9 million in sales in the fourth quarter of 2015. Within six months of its launch the drug has been prescribed to treat about 55% of the people for whom it's currently approved. (AP, Boston Business Journal)

2. A new wearable sensor tracks the chemicals in sweat, which can provide physicians with real-time data about a patient's health. This type of sensor is different than Fitbits and other wearables that track heart rate, researchers said. (WSJ)

3. Johnson & Johnson developed a clinical trial that seeks to take a new approach to treating depression, by trying to lower inflammation in the body instead of focusing on changing chemicals in the brain. (Stat)

4. Fifty-six percent of participants in a Kaiser Family Foundation poll said that the cost of healthcare, health insurance and prescription drugs are very important in the upcoming presidential race, while 26% said these costs are an important factor to consider. (KFF)

5. Incyte said it halted a mid-stage clinical study that found its drug, Jakafi, did not sufficiently treat metastatic colorectal cancer. The drug is also being examined in a late-stage trial as a treatment for advanced pancreatic cancer. (Reuters)